Invest early for a piece of the action in China
This article was originally published in Clinica
Valued at $1,000 million in 1995 and growing at an estimated average of 30%, China's medical device market is the largest in Asia. However, most US firms doing business in China report that "the competition is stiff, that the multi-layered bureaucracy can be frustrating and expensive to deal with, and that profits are small", says US industry association HIMA in its newly-published 1996 Emerging Market Report.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.